EATG » EMA updates on Viekirax and Victrelis

EMA updates on Viekirax and Victrelis

  • Viekirax (ombitasvir/paritaprevir/ritonavir) – change to existing contraindication
    Contraindicated in patients with moderate hepatic impairment
    Read more here.

 

*******************

  • Victrelis (boceprevir) – withdrawal of marketing authorization
    The marketing authorisation for Victrelis has been withdrawn at the request of the marketing-authorisation holder.
    Read more here.
News categories: Hepatitis, EMA/FDA